
ALURD
Healthcare · Medical Devices · $1.8M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · +28.3% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 20, 2026 | Time not confirmed | -5.10 | -6.90 | -35.3% |
| Mar 30, 2026 | Before the open | -9.45 | -5.44 | +42.4% |
| Nov 12, 2025 | Before the open | -36.75 | -17.75 | +51.7% |
| Aug 19, 2025 | After the close | -13.35 | -13.10 | +1.9% |
| May 14, 2025 | Before the open | -23.55 | -18.45 | +21.7% |
| Mar 26, 2025 | Time not confirmed | — | -63.16 | — |
| Nov 13, 2024 | Before the open | -68.44 | -68.17 | +0.4% |
| Aug 13, 2024 | Before the open | -90.00 | 51.22 | +156.9% |
| May 14, 2024 | Before the open | -112.50 | 41.25 | +136.7% |
| Mar 21, 2024 | Time not confirmed | — | -168.20 | — |
| Nov 29, 2023 | Time not confirmed | — | -203.47 | — |
Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior…